[저자] Catherine J Reynolds, Corinna Pade, Joseph M Gibbons, Ashley D Otter, Kai-Min Lin, Diana Muñoz Sandoval, Franziska P Pieper, David K Butler, Siyi Liu, George Joy, Nasim Forooghi, Thomas A Treibel, Charlotte Manisty, James C Moon, COVIDsortium Investigators§, COVIDsortium Immune Correlates Network§, Amanda Semper, Tim Brooks, Áine McKnight, Daniel M Altmann, Rosemary J Boyton, Hakam Abbass, Aderonke Abiodun, Mashael Alfarih, Zoe Alldis, Daniel M Altmann, Oliver E Amin, Mervyn Andiapen, Jessica Artico, João B Augusto, Georgina L Baca, Sasha N L Bailey, Anish N Bhuva, Alex Boulter, Ruth Bowles, Rosemary J Boyton, Olivia V Bracken, Ben O'Brien, Tim Brooks, Natalie Bullock, David K Butler, Gabriella Captur, Olivia Carr, Nicola Champion, Carmen Chan, Aneesh Chandran, Tom Coleman, Jorge Couto de Sousa, Xose Couto-Parada, Eleanor Cross, Teresa Cutino-Moguel, Silvia D'Arcangelo, Rhodri H Davies, Brooke Douglas, Cecilia Di Genova, Keenan Dieobi-Anene, Mariana O Diniz, Anaya Ellis, Karen Feehan, Malcolm Finlay, Marianna Fontana, Nasim Forooghi, Sasha Francis, Joseph M Gibbons, David Gillespie, Derek Gilroy, Matt Hamblin, Gabrielle Harker, Georgia Hemingway, Jacqueline Hewson, Wendy Heywood, Lauren M Hickling, Bethany Hicks, Aroon D Hingorani, Lee Howes, Ivie Itua, Victor Jardim, Wing-Yiu Jason Lee, Melaniepetra Jensen, Jessica Jones, Meleri Jones, George Joy, Vikas Kapil, Caoimhe Kelly, Hibba Kurdi, Jonathan Lambourne, Kai-Min Lin, Siyi Liu, Aaron Lloyd, Sarah Louth, Mala K Maini, Vineela Mandadapu, Charlotte Manisty, Áine McKnight, Katia Menacho, Celina Mfuko, Kevin Mills, Sebastian Millward, Oliver Mitchelmore, Christopher Moon, James Moon, Diana Muñoz Sandoval, Sam M Murray, Mahdad Noursadeghi, Ashley Otter, Corinna Pade, Susana Palma, Ruth Parker, Kush Patel, Mihaela Pawarova, Steffen E Petersen, Brian Piniera, Franziska P Pieper, Lisa Rannigan, Alicja Rapala, Catherine J Reynolds, Amy Richards, Matthew Robathan, Joshua Rosenheim, Cathy Rowe, Matthew Royds, Jane Sackville West, Genine Sambile, Nathalie M Schmidt, Hannah Selman, Amanda Semper, Andreas Seraphim, Mihaela Simion, Angelique Smit, Michelle Sugimoto, Leo Swadling, Stephen Taylor, Nigel Temperton, Stephen Thomas, George D Thornton, Thomas A Treibel, Art Tucker, Ann Varghese, Jessry Veerapen, Mohit Vijayakumar, Tim Warner, Sophie Welch, Hannah White, Theresa Wodehouse, Lucinda Wynne, Dan Zahedi, Benjamin Chain, James C Moon
[Category] COVID19(2023년), MERS, SARS, 변종, 진단,
[Article Type] Article
[Source] PMC
Abstract
The Omicron, or Pango lineage B.1.1.529, variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and partial neutralizing antibody (nAb) escape. Vaccinated individuals show protection against severe disease, often attributed to primed cellular immunity. We investigated T and B cell immunity against B.1.1.529 in triple BioNTech BNT162b2 messenger RNA-vaccinated health care workers (HCWs) with different SARS-CoV-2 infection histories. B and T cell immunity against previous variants of concern was enhanced in triple-vaccinated individuals, but the magnitude of T and B cell responses against B.1.1.529 spike protein was reduced. Immune imprinting by infection with the earlier B.1.1.7 (Alpha) variant resulted in less durable binding antibody against B.1.1.529. Previously infection-naïve HCWs who became infected during the B.1.1.529 wave showed enhanced immunity against earlier variants but reduced nAb potency and T cell responses against B.1.1.529 itself. Previous Wuhan Hu-1 infection abrogated T cell recognition and any enhanced cross-reactive neutralizing immunity on infection with B.1.1.529.
All Keywords
【초록키워드】 neutralizing antibody, SARS-CoV-2, coronavirus, Health care, Immunity, SARS-COV-2 infection, variant, Infection, variants of concern, severe acute respiratory syndrome Coronavirus, omicron, Spike protein, B cell, BNT162b2, T cell, Transmissibility, cellular immunity, B.1.1.7, HCWs, spike mutation, T cell responses, Wuhan, Lineage, Health care worker, B.1.1.529, respiratory, T cell response, NAb, severe disease, binding antibody, B cell response, cross-reactive, HCW, (alpha, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, individual, vaccinated individuals, T and B cell responses, neutralizing immunity, investigated, reduced, less, magnitude, individuals, abrogated, was reduced, show protection against, 【제목키워드】 SARS-CoV-2,
{{{ 추상적인 }}}
중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)의 변종인 오미크론(Pango lineage) B.1.1.529는 높은 전염성과 부분 중화 항체(nAb) 탈출을 통해 다중 스파이크 돌연변이를 가지고 있습니다. 백신 접종을 받은 사람들은 종종 프라이밍된 세포 면역에 기인하는 심각한 질병에 대한 보호를 보여줍니다. 우리는 SARS-CoV-2 감염 이력이 서로 다른 삼중 BioNTech BNT162b2 메신저 RNA 백신 접종 의료 종사자(HCW)에서 B.1.1.529에 대한 T 및 B 세포 면역을 조사했습니다. 우려되는 이전 변이체에 대한 B 및 T 세포 면역은 삼중 백신 접종된 개인에서 향상되었지만 B.1.1.529 스파이크 단백질에 대한 T 및 B 세포 반응의 크기는 감소했습니다. 이전 B.1.1.7(알파) 변이체에 의한 감염에 의한 면역 각인은 B.1.1.529에 대한 내구성이 약한 결합 항체를 생성했습니다. B.1.1.529 파동 동안 감염되었던 이전에 감염 경험이 없는 HCW는 이전 변이체에 대해 향상된 면역성을 나타내었지만 B.1.1.529 자체에 대한 nAb 효능 및 T 세포 반응을 감소시켰습니다. 이전의 우한 Hu-1 감염은 B.1.1.529 감염 시 T 세포 인식 및 강화된 교차 반응성 중화 면역을 폐지했습니다.